The newest classes of anti-diabetic medications are increasingly valued not just for their glucose-lowering effects, but for their demonstrated benefits in protecting the cardiovascular and renal systems—major complication areas in chronic endocrine disease. Sodium-Glucose Co-transporter 2 (SGLT-2) Inhibitors, such as Empagliflozin and Dapagliflozin, exemplify this shift toward holistic...
For individuals with Type 1 Diabetes and advanced Type 2 Diabetes, the foundation of treatment remains insulin, but the quality of life is being dramatically improved by new insulin analogues and novel delivery methods. The goal is to more closely mimic the body's natural physiological insulin response.
Ultra-long-acting insulin analogues, such as insulin icodec, are being developed to allow...
Russian 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Romaian
Portuguese (Brazil)
Tiếng Việt